Opendata, web and dolomites

MEXOM SIGNED

Development and characterization of extracellular vesicles an innovative cell-free therapeutical product for treatment of stroke

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEXOM project word cloud

Explore the words cloud of the MEXOM project. It provides you a very rough idea of what is the project "MEXOM" about.

glp    candidate    independent    mechanism    stem    indicate    receive    preclinical    vesicles    career    transferable    intellectual    stroke    treatment    training    civil    demonstrated    inflammation    academia    private    extracellular    human    brain    medical    msc    manufacturing    commercial    highlight    policymakers    secreted    regulations    action    reinforce    vitro    gmp    data    vivo    world    worldwide    innovation    cell    biology    experiments    failed    advancing    mscs    molecules    communication    cargo    time    ex    public    stakeholders    entrepreneurship    scientist    models    grade    host    molecule    unmet    anti    innovations    micrornas    property    cells    cord    inflammatory    clinically    first    regenerative    evs    deleterious    immunomodulatory    fellowship    exert    skills    plays    boosted    applicable    ischemic    leader    molecular    societies    mature    he    acute    small    preconditioning    assurance    clinical    enrichment    medicine    disability    competences    researcher    quality    acquire    transfer    industry    mesenchymal    effect    vital   

Project "MEXOM" data sheet

The following table provides information about the project.

Coordinator
THE CELL-FACTORY 

Organization address
address: GALILEILAAN 19
city: NIEL
postcode: 2845
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2018
 Duration (year-month-day) from 2018-09-03   to  2020-09-02

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CELL-FACTORY BE (NIEL) coordinator 160˙800.00

Map

 Project objective

Stroke is leading cause of long-term disability in Europe and worldwide with no effective treatment so far. Inflammation plays a vital role in brain’s response to ischemic stroke with deleterious consequences during early acute phase. Strong immunomodulatory effect of human mesenchymal stem cell (MSCs) demonstrated in many preclinical stroke models, however, has failed in clinical experiments. Recent preclinical data indicate that MSCs exert their anti-inflammatory effects via secreted extracellular vesicles (EVs) through microRNAs and this potential could be boosted by preconditioning MSCs ex vivo with small molecules. The aim of this Fellowship will be the determination of MSC-EVs anti-inflammatory mechanism of action specific for stroke for the first time.

The Host has developed clinical-grade technology (GLP/GMP) for human cord MSC-EVs manufacturing at large scale with anti-inflammatory action. During this Project the Researcher will receive training-through-research and will investigate the small molecule potential impact on MSC-EVs cargo enrichment with specific microRNAs. Then he will study candidate microRNAs anti-inflammatory potential in vitro on the key brain inflammation cells. The Researcher will acquire transferable knowledge in regulations, quality assurance, intellectual property and entrepreneurship. Novel competences will reinforce the Researcher as mature and independent scientist in the field of regenerative medicine with new career opportunities in private sector. Communication and dissemination will be carried out with all stakeholders, including academia, industry, civil societies, policymakers and general public.

The Researcher will transfer his molecular biology knowledge and skills, thus advancing the development of MSC-EVs product for treatment of stroke at the Host towards clinically applicable commercial innovation. This Fellowship will highlight Europe as world leader in innovations targeting unmet medical needs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEXOM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEXOM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

5G-ACE (2019)

Beyond 5G: 3D Network Modelling for THz-based Ultra-Fast Small Cells

Read More  

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More